Mechanism of lipid mobilization associated with cancer cachexia: interaction between the polyunsaturated fatty acid, eicosapentaenoic acid, and inhibitory guanine nucleotide-regulatory protein.
During a study of the mechanism of cancer cachexia, a debilitating condition in which catabolism of host muscle and adipose tissue occurs, it has been observed that the process can be effectively reversed in vivo by the polyunsaturated fatty acid, eicosapentaenoic acid (EPA), but not by other PUFA of either the n-3 or n-6 series. In vitro studies showed that EPA blocked the action of a tumour-produced catabolic factor at the level of the adipocyte, and that the effect of EPA also extended to beta-adrenergic stimuli and polypeptide hormones. Again the effect was specific to EPA and appeared to arise from an inhibition of the elevation of cyclic AMP levels in adipocytes in response to varied stimuli. Using isoprenaline stimulated lipolysis as a model system we have shown that EPA has a direct inhibitory effect on isoprenaline-stimulated adenylate cyclase in isolated plasma membrane fractions with half maximal inhibition at a concentration of 165 microM. The inhibitory effect was specific for EPA and was not shown by docosahexaenoic or arachidonic acids. The inhibitory effect of EPA on adenylate cyclase showed properties similar to hormonal inhibition of the enzyme in that it was (i) GTP-dependent, (ii) non-competitive with isoprenaline, (iii) eliminated following treatment of either adipocytes or plasma membrane fractions with pertussis toxin, which is known to ADP-ribosylate the alpha-subunit of an inhibitory guanine nucleotide-regulatory protein (Gi), thus leading to its inactivation. This suggests that inhibition of cyclic AMP formation by EPA was due, at least in part, to a Gi-mediated inhibition of adenylate cyclase activity.(ABSTRACT TRUNCATED AT 250 WORDS)
Tisdale
M J
MJ
Pharmaceutical Sciences Institute, Aston University, Birmingham, UK.
D000230:Adenocarcinoma / Q000150:complications / Q000188:drug therapy; D000262:Adenylyl Cyclases / Q000378:metabolism; D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D002100:Cachexia / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology; D003110:Colonic Neoplasms / Q000150:complications / Q000188:drug therapy; D000242:Cyclic AMP / Q000378:metabolism; D004041:Dietary Fats / Q000494:pharmacology; D015118:Eicosapentaenoic Acid / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D004789:Enzyme Activation / Q000187:drug effects; D015525:Fatty Acids, Omega-3 / Q000494:pharmacology / Q000627:therapeutic use; D005231:Fatty Acids, Unsaturated / Q000378:metabolism*; D019204:GTP-Binding Proteins / Q000378:metabolism*; D005786:Gene Expression Regulation / Q000187:drug effects; D011905:Genes, ras / Q000187:drug effects; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology; D019787:Linoleic Acid; D008041:Linoleic Acids / Q000378:metabolism / Q000494:pharmacology / Q000633:toxicity; D050356:Lipid Metabolism; D008066:Lipolysis / Q000187:drug effects; D051379:Mice; D009369:Neoplasms / Q000150:complications* / Q000378:metabolism / Q000503:physiopathology; D015398:Signal Transduction / Q000187:drug effects
D004041:Dietary Fats; D015525:Fatty Acids, Omega-3; D005231:Fatty Acids, Unsaturated; D008041:Linoleic Acids; D019787:Linoleic Acid; D015118:Eicosapentaenoic Acid; D000242:Cyclic AMP; D019204:GTP-Binding Proteins; D000262:Adenylyl Cyclases; D007545:Isoproterenol